Balanced news tone
News Sentiment
BDX sentiment intelligence
BCAL Diagnostics Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
86/100 classification confidence.
directly relevant articles
high-authority source matches
-2.7% over one week, +4.3% over four weeks, trend inactive, and below fair value.
Qiagen stock holds steady as diagnostics demand shapes long term outlook
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Qiagen stock holds steady as diagnostics demand shapes long term outlook
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 14 Jul 2026 09:00
- Source
- Ad Hoc News
Why Did BCAL Diagnostics Ltd (ASX: BDX) Jump 12.33%?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 06:25
- Source
- Kalkine
Qiagen stock holds steady as diagnostics demand supports long-term growth
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 13 Jul 2026 06:08
- Source
- Ad Hoc News
Qiagen stock reflects steady diagnostics demand as investors weigh long-term growth drivers
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 12 Jul 2026 12:19
- Source
- Ad Hoc News
Roche stock holds steady as pharma giant leans on diagnostics and oncology strength
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 08:31
- Source
- Ad Hoc News
Labcorp stock holds its business focus. Clinical diagnostics remain the core.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 09:51
- Source
- Ad Hoc News
Price to sales forward of BCAL Diagnostics Limited – ASX:BDX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 12:36
- Source
- TradingView
Qiagen N.V. highlights molecular diagnostics growth as investors eye global health demand
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 06 Jul 2026 06:41
- Source
- Ad Hoc News
BCAL Diagnostics (ASX:BDX) Expands Diagnostics Strategy with New Investment
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Kalkine
BCAL Diagnostics Crosses 10% Threshold in Genetic Signatures with $1.39 Million Share Purchase
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Kalkine
BCAL Diagnostics Secures $4.9 Million Convertible Note Top-Up and $1.4 Million R&D Tax Offset to Fund FY2027 Cancer Detection Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 02:32
- Source
- Kalkine
Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:11
- Source
- Ad Hoc News
Quest Diagnostics Stock - Analyst targets, sector review and weekly recap
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 19 Jun 2026 16:09
- Source
- Ad Hoc News
BCAL Diagnostics (ASX:BDX): The Breast Cancer Blood Test Story Investors Are Watching in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Kalkine
BCAL Diagnostics develops breast cancer test with 91% sensitivity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 05:33
- Source
- grafa.com
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- smallcaps.com.au
BCAL (ASX:BDX) Diagnostics Expands National Access to Early Cancer Detection Blood Tests
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Kalkine
BCAL Diagnostics (ASX:BDX) Shares Rally on Expansion of National Cancer Test Access
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 May 2026 07:00
- Source
- Kalkine
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- smallcaps.com.au
Bcal Diagnostics (ASX:BDX)-What the Latest Share Price Drop Means for Investors?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- Kalkine
BCAL Diagnostics (ASX:BDX) Secures Exclusive Licence for Cancer Blood Tests in Australia and New Zealand
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Sep 2025 07:00
- Source
- Kalkine
BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Mar 2025 07:00
- Source
- Investing News Network
BCAL Diagnostics Limited (ASX: BDX) - Share Price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jul 2021 15:38
- Source
- intelligentinvestor.com.au